VIR Vir Biotechnology Inc.

33.69
-3.37  -9%
Previous Close 37.06
Open 37.11
Price To Book 10.43
Market Cap 3,972,112,552
Shares 117,901,827
Volume 2,590,938
Short Ratio
Av. Daily Volume 1,320,865
Stock charts supplied by TradingView

NewsSee all news

  1. Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature

    Human antibody potently neutralizes SARS-CoV-2 and related viruses, suggesting high barrier to resistance Clinical testing expected to begin this summer in collaboration with GSK SAN FRANCISCO, May 18, 2020 (GLOBE

  2. Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

    SAN FRANCISCO, May 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate

  3. Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

    SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders

  4. Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference

    SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George

  5. Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19

    − Highly Potent and Broadly Cross-Reactive RNAi Therapeutic Development Candidate Selected Only Three Months After Program Initiation − − Companies Expect to Start Human Clinical Trials at or Around Year-End 2020

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to commence 2H 2020.
VIR-2218 and pegylated interferon-alpha
Chronic hepatitis B virus (HBV)
Phase 2 data due 1H 2021.
VIR-2482
Influenza
Phase 1/2 trial to commence summer 2020.
Antibody Platform
Coronavirus COVID-19
Human trials to commence around the end of 2020.
VIR-2703
COVID-19

Latest News

  1. Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature

    Human antibody potently neutralizes SARS-CoV-2 and related viruses, suggesting high barrier to resistance Clinical testing expected to begin this summer in collaboration with GSK SAN FRANCISCO, May 18, 2020 (GLOBE

  2. Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

    SAN FRANCISCO, May 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate

  3. Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

    SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders

  4. Vir Biotechnology to Present at BofA Securities 2020 Health Care Conference

    SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George

  5. Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19

    − Highly Potent and Broadly Cross-Reactive RNAi Therapeutic Development Candidate Selected Only Three Months After Program Initiation − − Companies Expect to Start Human Clinical Trials at or Around Year-End 2020

  6. Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020

    SAN FRANCISCO, April 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will

  7. VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

    SAN FRANCISCO, April 15, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced additional interim data from the ongoing Phase 2 trial in patients and results from the Phase 1 trial in healthy

  8. Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment

    SONGDO, South Korea and SAN FRANCISCO, April 9, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and Vir Biotechnology, Inc. (NASDAQ:VIR) today announced a manufacturing agreement under which Samsung Biologics will

  9. Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218

  10. Vir Biotechnology, Inc. (FormDEFA14A)

  11. Vir Biotechnology, Inc. (FormDEF 14A)

  12. GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

    Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaksPromising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical

  13. Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19

    − Collaboration to Evaluate RNAi Therapeutics Targeting Three Host Factors Required for SARS-CoV-2 Infection, Including ACE2 and TMPRSS2 − − Vir to Lead Development of Potential Coronavirus RNAi Therapeutic Candidates

  14. Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19

    Generation Bio and Vir Biotechnology (NASDAQ:VIR) today announced a collaborative research agreement to explore the potential for Generation Bio's non-viral gene therapy platform to extend the impact and reach of Vir's

  15. Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

    SAN FRANCISCO, March 26, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate

  16. WuXi Biologics Achieved Remarkable Results in 2019

    57.2% Revenue Growth to RMB3,983.7 Million 63.0% Gross Profit Growth to RMB1,658.8 Million Adjusted Net Profit Up 60.3% to RMB1,205.0 Million Diluted EPS of RMB0.76 and Adjusted Diluted EPS of RMB0.91, Increasing 58.3%

  17. Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19

    - Multiple antibodies identified that neutralize SARS-CoV-2- Phase 1/2 clinical testing planned for this summer SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today

  18. Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19

    SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that it has signed a letter of intent with Biogen Inc. (NASDAQ:BIIB) for the development and clinical manufacturing

  19. Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses

    SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced a research collaboration agreement with the National Institutes of Health (NIH) and the National Institute of

  20. Vir Biotechnology to Present at Barclays Global Healthcare Conference

    SAN FRANCISCO, March 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today

  21. Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19

     — Recent Alnylam advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses — Vir to lead development of potential coronavirus RNAi therapeutic candidates,

  22. Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19

    SAN FRANCISCO and SHANGHAI, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) and WuXi Biologics (stock code: 2269.HK) today announced a development and manufacturing collaboration to

  23. WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19

    SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics

  24. Vir Biotechnology to Present at 40th Annual Cowen Healthcare Conference

    SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today

  25. Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2

    SAN FRANCISCO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, today

  26. Vir Biotechnology applying multiple platforms to address public heath risk from Wuhan coronavirus

    SAN FRANCISCO, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on immune approaches to treating and preventing serious infectious diseases, is issuing

  27. Vir Biotechnology to Provide Pipeline Update at 38th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent

  28. Sundial and Vir Pharmaceuticals Sign Medical Cannabis Supply Agreement for Australian Chronic Pain Clinical Studies

    CALGARY and SYDNEY, Jan. 9, 2020 /CNW/ - Sundial Growers Inc. (NASDAQ:SNDL) ("Sundial"), a Canadian licensed cannabis producer and Vir Pharma Holdings Pty Ltd.  (NASDAQ:VIR) ("Vir Pharma"), an Australian

  29. Vir Biotechnology to Present at 38th Annual J.P. Morgan Healthcare Conference

    SAN FRANCISCO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent

  30. Brii Biosciences Expands Infectious Disease Pipeline

    Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases Company pipeline now includes up to 12 partnered assets, in addition to internal development

  31. Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    SAN FRANCISCO, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent